TL;DR: A randomised controlled trial will be conducted to assess the efficacy, cost-utility and reach of Oncokompas as an eHealth self-management application compared with care as usual among cancer survivors.
Abstract: Cancer survivors have to deal with a wide range of physical symptoms, psychological, social and existential concerns, and lifestyle issues related to cancer and its treatment Therefore, it is essential that they have access to optimal supportive care services The eHealth self-management application Oncokompas was developed to support cancer survivors with where they need to turn to for advice and guidance, as well as to increase their knowledge on the availability of optimal support A randomised controlled trial will be conducted to assess the efficacy, cost-utility and reach of Oncokompas as an eHealth self-management application compared with care as usual among cancer survivors Adult cancer survivors diagnosed with breast, colorectal or head and neck cancer or lymphoma who are at 3 months to 5 years since curative treatment will be included In total, 544 cancer survivors will be randomly assigned to the intervention group or a wait-list control group The primary outcome measure is patient activation Secondary outcome measures include self-efficacy, personal control, perceived patient-physician interaction, need for supportive care, mental adjustment to cancer and health-related quality of life Furthermore, cost-utility outcomes will be assessed Reach is defined as the percentage of cancer survivors who get access to Oncokompas within the context of this trial Questionnaires will be administered at baseline, post-intervention and at 3- and 6-month follow-up In this study, we will evaluate the efficacy and cost-utility of Oncokompas among cancer survivors, as well as the reach of Oncokompas These are essential first steps in the translation of research into practice and contribute to sustainable adoption, implementation and maintenance of an evidence-based Oncokompas Netherlands Trial Register identifier: NTR5774
Registered on 8 March 2016
TL;DR: The staff costs for a variety of strategies used to recruit participants to a randomized supportive care study for couples who were within 18 months of a prostate cancer diagnosis are described.
TL;DR: The most striking finding was the presumed burden of study participation by the majority of parents as the main argument against randomization in pediatric oncology patients in supportive care studies is challenging.
Abstract: Purpose Treatment protocols in pediatric oncology have historically known high accrual rates, up to 94 %. Accrual for supportive care studies on the other hand appears to be a challenge. The aim of this study was to search for reasons explaining this poor accrual and for possible interventions to improve patient enrolment. Methods The failure screen log of our supportive care study (the Aristocaths study) was analyzed, and subsequently, a literature search was performed. Results The literature search (1985–2011) revealed three factors that can influence accrual. Firstly, study implementation and patient enrolment can be facilitated by appointing a dedicated clinical investigator in all participating centers and by facilitating clinical research nurses. Furthermore, adequate and tailor-made information is required for families to make a well-informed decision regarding study participation. Lastly, sufficient time should be assured for the process of decision making, especially since the number of eligible studies is increasing rapidly. Concerning our study, all three elements were met, but the most striking finding was the presumed burden of study participation by the majority of parents (82 %) as the main argument against randomization. Conclusions Accrual of pediatric oncology patients in supportive care studies is challenging. Nevertheless, welldesigned randomized controlled trials in supportive care will be essential for the improvement of pediatric cancer care. Therefore, we will need to increase awareness through (inter)national supportive care working groups regarding the need for supportive care trials and stimulate accrual when such trials are open.
TL;DR: Compared to other medical professionals, the involvement of radiation oncologists in cancer pain management remains marginal, at least in Italy.
Abstract: AimsTo assess the contribution of radiation oncologists in Italy in current management of breakthrough pain (BtP).MethodsIn 2012, the Palliative and Supportive Care Study Group of the Italian Assoc...